Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin

被引:3
|
作者
Fujii, Miharu [1 ]
Yasuda, Kaori [1 ]
Sakaki, Toshiyuki [1 ]
机构
[1] Toyama Prefectural Univ, Fac Engn, Dept Pharmaceut Engn, 5180 Kurokawa, Imizu, Toyama 9390398, Japan
关键词
Sesamin; Warfarin; CYP2C9; Human liver microsomes; Competitive inhibition; ANTIOXIDATIVE METABOLITES; EPISESAMIN; LIVER; CYTOCHROME-P450; LIGNAN;
D O I
10.1016/j.dmpk.2020.05.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A recent report demonstrated that sesamin strongly and non-competitively inhibits S-warfarin 7-hydroxylation activity in human liver microsomes with a K-i value of 0.2 mu M. This finding suggests that sesamin predominantly binds to CYP2C9 at another site for which it has a higher affinity than its affinity for the active site, thereby inhibiting the activity of CYP2C9 non-competitively. In this study, we found that sesamin competitively inhibited the 7-hydroxylation activity of S-warfarin in human liver microsomes with a K-i value of 15.7 mu M. In addition, the recombinant CYP2C9-dependent 7-hydroxylation activity of S-warfarin was competitively inhibited by sesamin with a Ki value of 13.1 mu M. These results are consistent with the fact that sesamin is a good substrate of CYP2C9, and its activity follows Michaelis-Menten kinetics. As the plasma concentration of sesamin after its administration is usually lower than 0.01 mu M, the inhibition of S-warfarin metabolism by sesamin does not appear to be severe. (C) 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 42 条
  • [1] Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation
    Zhang, ZY
    Kerr, J
    Wexler, RS
    Li, HY
    Robinson, AJ
    Harlow, PP
    Kaminsky, LS
    THROMBOSIS RESEARCH, 1997, 88 (04) : 389 - 398
  • [2] Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3)
    Shiozawa, Ayaka
    Yamaori, Satoshi
    Kamijo, Shinobu
    Ohmori, Shigeru
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 36
  • [3] Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3
    Iwakawa, Seigo
    Miyashita, Kenji
    Hashimoto, Yasuaki
    Kuroda, Tsutomu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (09) : 1983 - 1985
  • [4] Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin
    Pavani, Addepalli
    Naushad, Shaik Mohammad
    Stanley, Balraj Alex
    Kamakshi, Renganathan Gnanambal
    Abinaya, Krishnan
    Rao, Malempati Amaresh
    Uma, Addepally
    Kutala, Vijay Kumar
    PHARMACOGENOMICS, 2015, 16 (04) : 393 - 400
  • [5] R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9
    Yong, Wei Peng
    Kim, Tae Won
    Undevia, Samir D.
    Innocenti, Federico
    Ratain, Mark J.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1904 - 1908
  • [6] In Vitro Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod: Possible Mechanism of Iguratimod-Warfarin Interaction
    Yamaori, Satoshi
    Takami, Ken
    Shiozawa, Ayaka
    Sakuyama, Kanako
    Matsuzawa, Naoki
    Ohmori, Shigeru
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (03) : 441 - 447
  • [7] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Myong-Jin Kim
    Anne N. Nafziger
    Angela D. M. Kashuba
    Julia Kirchheiner
    Steffen Bauer
    Andrea Gaedigk
    Joseph S. Bertino
    European Journal of Clinical Pharmacology, 2006, 62 : 431 - 436
  • [8] CYP2C9 Genotype-DependentWarfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R-and S-Warfarin and Their Oxidative Metabolites
    Flora, Darcy R.
    Rettie, Allan E.
    Brundage, Richard C.
    Tracy, Timothy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (03) : 382 - 393
  • [9] Effect of Ethanol on S-Warfarin and Diclofenac Metabolism by Recombinant Human CYP2C9.1
    Tatsumi, Akitoshi
    Ikegami, Yuki
    Morii, Ryoko
    Sugiyama, Masatoshi
    Kadobayashi, Muneo
    Iwakawa, Seigo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2009, 32 (03) : 517 - 519
  • [10] Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9
    Kerenaftali Klein
    Ivelina Gueorguieva
    Leon Aarons
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 147 - 160